Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

Marie Skłodowska-Curie Action · Running

HER-CARE Hereditary and Early onset breast cancer: Comprehensive personalized Assessment, early Risk Evaluation, and clinical management

Coordinator
Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis, Netherlands
Runs
1 January 2026 to 31 December 2029
Status
Running
EU funding
€4.7m
Total cost
—
Partners
33 organisations in 13 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101227105

What the project is doing

In the project's own words, from its summary on CORDIS.

Breast cancer is the most frequently diagnosed cancer in women, with European countries having some of the highest age-standardized incident rates of early-onset (< age 50) breast cancer in the world. Yet, our understanding of the genetic and environmental factors triggering the pathophysiology of the disease in young women is still limited. Advancing breast cancer prevention and treatment demands a holistic approach towards an accurate and early tumour detection – strongly linked with better clinical outcomes.

HER-CARE aims to revolutionize the approach to hereditary and early-onset breast cancer through an innovative, interdisciplinary research and training program. The project will address critical gaps in early detection, risk stratification, and clinical management by developing tools that integrate genetic, molecular, and imaging data with state-of-the-art technologies, including artificial intelligence, machine learning, and advanced statistical modelling.

These efforts will uncover: i) new molecular mechanisms and biological targets that can be targeted in hereditary and early-onset breast cancer; ii) better multifactorial risk profiles to enhance prediction accuracy; iii) new minimally invasive tools and assays to detect and intercept breast cancer early. The resulting tools and methodologies will: enhance early detection with accessible, personalized treatment and preventative strategies tailored to young women; ii) improve genetic counselling and clinical management; iii) improve treatment guidelines/ cancer prevention programs; and iv) reduce the high rate of misdiagnoses and overtreatment.

HER-CARE will train the next generation of researchers by equipping 15 Doctoral Candidates with multidisciplinary skills spanning genetics, bioinformatics, molecular biology, cancer epidemiology, biostatistics, and computational science to transform the management of hereditary and early-onset breast cancer.

Topics

Who is involved

OrganisationCityCountryRole
Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek ZiekenhuisAmsterdamNetherlandsCoordinator
Medizinische Universitaet WienWienAustriaParticipant
QIMR Berghofer Medical Research InstituteHerstonAustraliaAssociatedpartner
Sophia Genetics SASaint-SulpiceSwitzerlandAssociatedpartner
Kypriako Idryma Erevnon Gia Ti Myiki DistrofiaAgios DometiosCyprusParticipant
Stremble Ventures LtdLimassolCyprusAssociatedpartner
Masarykova univerzitaBrnoCzechiaAssociatedpartner
Klinikum Der Universitaet Zu KoelnKoelnGermanyAssociatedpartner
Siemens Healthineers AGForchheimGermanyAssociatedpartner
Region SyddanmarkVejleDenmarkParticipant
Syddansk UniversitetOdense MDenmarkAssociatedpartner
Consorcio Para La Explotacion Del Centro Nacional De Analisis GenomicoBarcelonaSpainParticipant
Universitat De BarcelonaBarcelonaSpainAssociatedpartner
Institut Gustave RoussyVillejuifFranceParticipant
Universite Paris-SaclayGif-Sur-YvetteFranceAssociatedpartner
Academisch Ziekenhuis LeidenLeidenNetherlandsAssociatedpartner
Evidencio BVHaaksbergenNetherlandsParticipant
Methylomics B.V.NootdorpNetherlandsAssociatedpartner
Stichting Koningin Wilhelmina Fonds Voor De Nederlandse KankerbestrijdingAmsterdamNetherlandsAssociatedpartner
Stichting Radboud Universitair Medisch CentrumNijmegenNetherlandsAssociatedpartner
Universiteit TwenteEnschedeNetherlandsAssociatedpartner
Universiteit UtrechtUtrechtNetherlandsParticipant
Karolinska InstitutetStockholmSwedenParticipant
Astrazeneca UK LimitedCambridgeUnited KingdomAssociatedpartner
Foundation for Genomics & Population HealthCambridgeUnited KingdomAssociatedpartner
Institute of Cancer Research: the Royal Cancer Hospital LbgLondonUnited KingdomParticipant
Oxford Nanopore Technologies LtdOxfordUnited KingdomAssociatedpartner
Proteotype Diagnostics LtdCambridgeUnited KingdomParticipant
The Chancellor Masters and Scholars of the University of CambridgeCambridgeUnited KingdomParticipant
The Chancellor, Masters and Scholars of the University of OxfordOxfordUnited KingdomAssociatedpartner
Johns Hopkins UniversityBaltimoreUnited StatesAssociatedpartner
Veracyte, Inc.South San FranciscoUnited StatesAssociatedpartner
iCAD, IncNashuaUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS